The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone
Open accessAbstract
Improved understanding of the adverse pharmacological properties of aldosterone has prompted investigation of the clinical benefits of blocking aldosterone at the receptor level. This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and eplerenone. A Medline search identified clinical studies assessing spironolactone and eplerenone. Priority was given to large, well‐controlled, clinical trials and comparative studies. Pharmacological differences between spironolactone and eplerenone include lower affinity of eplerenone for progesterone, androgen, and glucocorticoid receptors; more consistently demonstrated nongenomic properties for eplerenone; and the presence of long‐acting metabolites for spironolactone. Both agents effectively treat hypertension and heart failure but comparisons are complicated by the deficiency of head‐to‐head trials and differences between patient populations. There are differences in the tolerability profiles; spironolactone is associated with dose‐dependent sexual side effects. Both agents produce dose‐dependent increases in potassium concentrations, although the effect with spironolactone appears to be greater when both agents are administered at recommended doses. Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events. Copyright © 2008 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R. A., Roniker, B., Kleiman, J., Krause, S., Burns, D., & Williams, G. H. (2003) · Circulation · doi:10.1161/01.cir.0000091405.00772.6e · Cited by 623
Self-citationEfficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 502
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 388
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343
White, W. B., Duprez, D., St Hillaire, R., Krause, S., Roniker, B., Kuse-Hamilton, J., & Weber, M. A. (2003) · Hypertension · doi:10.1161/01.hyp.0000067463.13172.ea · Cited by 295
Efficacy and tolerance of spironolactone in essential hypertension
Jeunemaitre, X., Chatellier, G., Kreft-Jais, C., Charru, A., Devries, C., Plouin, P.-F., Corvol, P., & Menard, J. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91030-7 · Cited by 276
Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients
Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., & Fakouhi, K. (2002) · Hypertension · doi:10.1161/01.hyp.0000025146.19104.fe · Cited by 210
Self-citationSica, D. A. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2345-1 · Cited by 192
The evolution of aldosterone antagonists
Garthwaite, S. M., & McMahon, E. G. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.005 · Cited by 189
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension
Williams, G. H., Burgess, E., Kolloch, R. E., Ruilope, L. M., Niegowska, J., Kipnes, M. S., Roniker, B., Patrick, J. L., & Krause, S. L. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.007 · Cited by 166
Self-citationMichea, L., Delpiano, A. M., Hitschfeld, C., Lobos, L., Lavandero, S., & Marusic, E. T. (2004) · Endocrinology · doi:10.1210/en.2004-1130 · Cited by 147
Short- and long-term neurohormonal activation following acute myocardial infarction
Sigurðsson, A. F., Held, P. H., & Swedberg, K. B. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90656-t · Cited by 139
Aldosterone induces contraction of the resistance arteries in man
Romagni, P., Rossi, F., Guerrini, L., Quirini, C., & Santiemma, V. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00363-5 · Cited by 137
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
Karagiannis, A. I., Τζιόμαλος, Κ., Papageorgiou, T., Kakafika, A. I., Pagourelias, E. D., Anagnostis, P. G., Athyros, V. G., & Mikhailidis, D. P. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.4.509 · Cited by 136
Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites
Gardiner, P., Schrode, K. B., Quinlan, D., Martin, B. K., Boreham, D. R., Rogers, M. S., Stubbs, K., Smith, M. E., & Karim, A. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03339.x · Cited by 133
The 45-year story of the development of an anti-aldosterone more specific than spironolactone
Ménard, J. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.008 · Cited by 111
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure
Tamirisa, K. P., Aaronson, K. D., & Koelling, T. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.10.005 · Cited by 99
Christ, M., Guenther, A., Heck, M., Schmidt, B. M. W., Falkenstein, E., & Wehling, M. (1999) · Circulation · doi:10.1161/01.cir.99.11.1485 · Cited by 95
Sexual dysfunction with antihypertensive and antipsychotic agents.
Smith, P. J., & Talbert, R. L. (1986) · PubMed · Cited by 88
Nongenomic Effects of Aldosterone in the Human Heart: Interaction With Angiotensin II
Chai, W., Garrelds, I. M., VRIES, R. D., Batenburg, W. W., van Kats, J. P., & Danser, A. H. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000182661.98259.4f · Cited by 88
Treatment of Heart Failure with Spironolactone — Trial and Tribulations
McMurray, J. J. V., & O’Meara, E. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048144 · Cited by 79
Controversy surrounding the safety of cerivastatin
Davidson, M. H. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.3.207 · Cited by 60
Aldosterone Rapidly Represses Protein Kinase C Activity in Neonatal Rat Cardiomyocytes in Vitro
Sato, A., Liu, J., & Funder, J. W. (1997) · Endocrinology · doi:10.1210/endo.138.8.5352 · Cited by 57
Fujita, M., Minamino, T., Asanuma, H., Sanada, S., Hirata, A., Wakeno, M., Myoishi, M., Okuda, H., Ogai, A., Okada, K.-I., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000171184.84077.80 · Cited by 51
Aldosterone blockade in cardiovascular disease
Struthers, A. D. (2004) · Heart · doi:10.1136/hrt.2003.025312 · Cited by 42
Self-citationCroom, K. F., & Perry, C. M. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505010-00007 · Cited by 35
Drug-induced sexual dysfunction
Goldstein, I., & Krane, R. J. (1983) · World Journal of Urology · doi:10.1007/bf00326809 · Cited by 30
Miyata, Y., Muto, S., & Kusano, E. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000194122.27475.6c · Cited by 30
Cited by
Roles of Inflammation, Oxidative Stress, and Vascular Dysfunction in Hypertension
Dinh, Q. N., Drummond, G. R., Sobey, C. G., & Chrissobolis, S. (2014) · BioMed Research International · doi:10.1155/2014/406960 · Cited by 598
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Boorsma, E. M., ter Maaten, J. M., Damman, K., Dinh, W., Gustafsson, F., Goldsmith, S., Burkhoff, D., Zannad, F., Udelson, J. E., & Voors, A. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0379-7 · Cited by 365
Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy
Bader, M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105610 · Cited by 345
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.58 · Cited by 319
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Metadata
- Authors
- Struthers, A., Krum, H., & Williams, G. H.
- Venue
- Clinical Cardiology
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 31
- Issue
- 4
- Pages
- 153-158
- ISSN
- 0160-9289 (ISSN-L)
- 1932-8737
- OpenAlex
- W2062266308
- Cited by
- 267
- References
- 30
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.